Skip to content
★ Sign in to follow
Total declarations
17
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (15 ops.)
€788k

Latest filing published 24 Mar 2006 for NEKTAR THERAPEUTICS, €4,921.

Insider track record

Disclosed buys
0
Disclosed sells
15
Signal history

No signal scores available.

Ajit Gill: trading record in brief

All filings by Ajit Gill on record concern Nektar Therapeutics. The record holds 17 filings, for trades running from 11 January 2006 to 23 March 2006.

No open-market purchase appears, only 15 sales worth €788k. Besides market trades, the filings include 1 share grant and 1 option exercise.

The latest filing, published on 24 March 2006, reports an open-market sale of €4,921 in Nektar Therapeutics. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Ajit Gill

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations17 total
  • ▼
    President & CEOExecutivesNektar Therapeutics
    5,892 USD0SEC
    300 shares@ US$19.64Common StockSEC:0001179110-06-007193:0
  • ▼
    President & CEOExecutivesNektar Therapeutics
    11,766 USD0SEC
    600 shares@ US$19.61Common StockSEC:0001179110-06-007193:1
  • ▼
    President & CEOExecutivesNektar Therapeutics
    9,815 USD0SEC
    500 shares@ US$19.63Common StockSEC:0001179110-06-007193:2
  • ▼
    President & CEOExecutivesNektar Therapeutics
    3,916 USD0SEC
    200 shares@ US$19.58Common StockSEC:0001179110-06-007193:3
  • ▼
    President & CEOExecutivesNektar Therapeutics
    1,959 USD0SEC
    100 shares@ US$19.59Common StockSEC:0001179110-06-007193:4
  • ▼
    President & CEOExecutivesNektar Therapeutics
    21,266 USD0SEC
    1,085 shares@ US$19.60Common StockSEC:0001179110-06-007193:5
  • ▼
    President & CEOExecutivesNektar Therapeutics
    14,911 USD0SEC
    760 shares@ US$19.62Common StockSEC:0001179110-06-007193:6
  • ◆
    President & CEOExecutivesNektar Therapeutics
    100 USD0SEC
    10,000 shares@ US$0.01Common StockSEC:0001179110-06-005683:0
  • ▼
    President & CEOExecutivesNektar Therapeutics
    368,402 USD0SEC
    16,700 shares@ US$22.06Common StockSEC:0001179110-06-002323:0
  • ▼
    President & CEOExecutivesNektar Therapeutics
    293,531 USD0SEC
    13,300 shares@ US$22.07Common StockSEC:0001179110-06-002323:1
  • ▼
    President & CEOExecutivesNektar Therapeutics
    22,080 USD0SEC
    1,000 shares@ US$22.08Common StockSEC:0001179110-06-002323:2
  • ▼
    President & CEOExecutivesNektar Therapeutics
    53,016 USD0SEC
    2,400 shares@ US$22.09Common StockSEC:0001179110-06-002323:3
  • ▼
    President & CEOExecutivesNektar Therapeutics
    86,151 USD0SEC
    3,900 shares@ US$22.09Common StockSEC:0001179110-06-002323:4
  • ▼
    President & CEOExecutivesNektar Therapeutics
    30,940 USD0SEC
    1,400 shares@ US$22.10Common StockSEC:0001179110-06-002323:5
  • ▼
    President & CEOExecutivesNektar Therapeutics
    13,260 USD0SEC
    600 shares@ US$22.10Common StockSEC:0001179110-06-002323:6
  • ▼
    President & CEOExecutivesNektar Therapeutics
    15,477 USD0SEC
    700 shares@ US$22.11Common StockSEC:0001179110-06-002323:7
  • ◇
    President & CEOExecutivesNektar Therapeutics
    788,482 USD0SEC
    43,110 shares@ US$18.29Common StockSEC:0001179110-06-001390:0

17 of 17 declarations